Hematological Cancers Therapeutics: Immunotherapeutic Strategies to Reimagine Cancer Care

Cancer therapeutics typically involves the administration of anticancer agents such as chemotherapy and oncology drugs for the treatment of cancers. Across the globe, blood malignancies rank as the fifth most prevalent cancer and are the second most cause of death due to cancer. Leukemia, lymphoma, and multiple myeloma are the three most common hematological cancer types, out of which lymphoma is the most common hematological malignancy. Some of the most common therapeutics for hematological cancer are stem cell transplantation, chemotherapy, and radiation therapy. The course of treatment generally depends on the type of cancer, rate of progression, the spread of cancer, and other vital aspects. 

The market growth is being driven by the increasing incidences of hematological cancers and increasing research and development activities to develop new and innovative cancer treatments. Moreover, rising collaborations between pharmaceutical companies and research institutes to design and develop innovative therapeutics for hematological cancers is adding traction to the market. The ongoing research activities by key pharmaceutical companies and research institutions are broadening the horizon of cancer therapies and their mode of action and effectiveness. This is, in turn, driving the growth of the market for hematological cancer therapeutics. Moreover, increasing awareness about various types of blood cancers via blood donation campaigns is playing a pivotal role in early diagnosis and treatment of cancer, thereby propelling the growth of the market. 

Some of the prominent players of the market are F. Hoffman-La Roche, Johnson & Johnson, Siemens AG, AbbVie, Bio-rad Laboratories, Abbott Laboratories, Karyopharm Therapeutics, HemoCue AB, Mindray Medical, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Celgene Corporation, and GlaxoSmithKline, Plc. Over the last few years, the market has witnessed significant mergers and acquisitions and collaborations to develop new and innovative products and therapeutic agents. 

Early diagnosis and high unmet clinical needs of cancer patients drive the companies to develop a new line of chemotherapy drugs and agents. In September 2020, ADC Therapeutics, a Swiss clinical-stage biotechnology company, submitted an application to the drug regulatory board in the U.S. for the approval of commercialization of loncastuximab tesirine as a third-line option for the treatment of Diffuse Large B-cell Lymphoma (DLBCL). In October 2020, Glycostem Therapeutics, a Netherlands-based biotech company, received U.S. FDA’s Orphan Drug Designation for its investigational therapeutic drug, oNKord treatment of multiple myeloma. ONK Therapeutics, a pre-clinical stage company that develops targeted NK-cell therapy for hematological cancers, closed a new round of financing at USD 8 million, which will be used to develop and expand its pre-clinical stage to propel the NK-cell therapy approach to human clinical trials. 

Read full press release at: https://www.reportsanddata.com/press-release/global-hematological-cancers-therapeutics-market